Welcome to LookChem.com Sign In|Join Free
  • or
3-(Benzyloxy)-2-methyl-4H-pyran-4-one is an organic compound that serves as an intermediate in the synthesis of various chemical products, particularly in the fragrance and flavor industries. It is characterized by its unique chemical structure, which contributes to its functional properties and applications.

61049-69-2

Post Buying Request

61049-69-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

61049-69-2 Usage

Uses

Used in Fragrance Industry:
3-(Benzyloxy)-2-methyl-4H-pyran-4-one is used as an intermediate for the synthesis of Malto (M160130), a fragrance molecule. Its chemical structure plays a crucial role in enhancing the overall scent profile of various fragrance products, making it a valuable component in the creation of unique and appealing scents.
Used in Flavor Industry:
In the flavor industry, 3-(Benzyloxy)-2-methyl-4H-pyran-4-one is utilized as an intermediate to produce compounds that contribute to the enhancement of taste and aroma in various food and beverage products. Its functional properties allow it to improve the overall sensory experience of these products, making it an essential component in the development of new and innovative flavors.

Check Digit Verification of cas no

The CAS Registry Mumber 61049-69-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,1,0,4 and 9 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 61049-69:
(7*6)+(6*1)+(5*0)+(4*4)+(3*9)+(2*6)+(1*9)=112
112 % 10 = 2
So 61049-69-2 is a valid CAS Registry Number.
InChI:InChI=1/C13H12O3/c1-10-13(12(14)7-8-15-10)16-9-11-5-3-2-4-6-11/h2-8H,9H2,1H3

61049-69-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-methyl-3-phenylmethoxypyran-4-one

1.2 Other means of identification

Product number -
Other names 2-Methyl-3-(phenylmethoxy)-4H-pyran-4-one

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:61049-69-2 SDS

61049-69-2Relevant academic research and scientific papers

Bifunctional 3-hydroxy-4-pyridinones as effective aluminium chelators: synthesis, solution equilibrium studies and in vivo evaluation

Irto, Anna,Cardiano, Paola,Chand, Karam,Cigala, Rosalia Maria,Crea, Francesco,De Stefano, Concetta,Gano, Lurdes,Sammartano, Silvio,Santos, Maria Amélia

, p. 116 - 129 (2018)

This paper reports the results on the study of a set of synthesized bifunctional 3-hydroxy-4-pyridinones chelators as potential aluminium sequestering agents. They were N-functionalized with alkyl-amino, -carboxylic and –(amino-carboxylic) groups, envisaging the improvement of the Al3+ sequestering capacity, in comparison with the marketed chelating drug deferiprone. The main focus of this work was given to the assessment of their binding ability towards Al3+, which was studied by potentiometric and UV–Vis spectrophotometric measurements carried out at T = 298.15 K. The speciation models were characterized by AlpLqHr (3p+r?qz) species with different stoichiometry. Depending on ligand side-chain structures and on their thermodynamic properties, different trends of stability was found. Furthermore, the sequestering ability of the ligands towards Al3+ was investigated by the calculation of pL0.5 values at different experimental conditions. These results clearly indicate that the presence of amino-carboxylic groups in the ligands increases the sequestering ability towards Al3+. The in silico evaluation of pharmacokinetic descriptors indicated no violation to the Lipinski's rule and drug-likeness properties. Furthermore, the in vivo bioassays on a model of metal-overload mice showed for three investigated ligands a higher metal-sequestering capacity than for the chelating drug deferiprone, thus suggesting their potential interest as Al-chelating drug candidates.

DIBI, a 3-hydroxypyridin-4-one chelator iron-binding polymer with enhanced antimicrobial activity

Ang, M. Trisha C.,Gumbau-Brisa, Roger,Allan, David S.,McDonald, Robert,Ferguson, Michael J.,Holbein, Bruce E.,Bierenstiel, Matthias

, p. 1206 - 1212 (2018)

Depriving microorganisms of bioavailable iron is a promising strategy for new anti-infective agents. The new, highly water-soluble, low molecular weight co-polymer DIBI was developed to selectively bind iron(iii) ions as a tris chelate and acts as a standalone anti-infective. Minimum inhibitory concentration (MIC) studies show DIBI is effective against representative reference strains for Gram-positive and Gram-negative bacteria S. aureus and A. baumannii, and the fungus C. albicans. Compared to the small molecule iron chelators, deferiprone and deferoxamine, DIBI outclassed these by factors of 100 to 1000 for inhibition of initial growth. DIBI and a series of related co-polymers (Mw of 2-9 kDa) were synthesized via reversible addition-fragmentation chain transfer (RAFT) polymerization of a chelating 3-hydroxypyridin-4-one (HPO) methacrylamide monomer and N-vinylpyrrolidone (NVP). Full incorporation of the HPO monomer into the co-polymers from the reaction solution was determined by 1H NMR spectroscopy and ranged from 4.6 to 25.6 mol%. UV-vis spectroscopy showed that all the HPO in DIBI binds readily to iron(iii) in a tris chelate mode to the maximum theoretical iron(iii) binding capacity of the co-polymer. Chemical characterization including single crystal X-ray diffraction analyses of the O-benzyl protected and the functional HPO monomer are discussed. By design, DIBI is highly water soluble; the highest mass fraction in water tested was 70% w/w, without the need of organic co-solvents.

New polyazamacrocyclic 3-hydroxy-4-pyridinone based ligands for iron depletion antitumor activity

Dong, Xiuxiu,He, Chuanchuan,Liu, Xiaoguang,Ma, Xiang,Xiang, Guangya,Zhang, Xiaojuan

, (2020)

Iron depletion is an efficient strategy for the development of anticancer agents. In an effort to develop efficient chelators, two new 3-hydroxy-4-pyridinone based polyazamacrocycles 1e and 2e were designed and synthesized. A preliminary study of the liga

In silico to in vitro screening of hydroxypyridinones as acetylcholinesterase inhibitors

Telpoukhovskaia, Maria A.,Patrick, Brian O.,Rodríguez-Rodríguez, Cristina,Orvig, Chris

, p. 1624 - 1628 (2016)

We have previously shown the improved acetylcholinesterase inhibitory activity of a model hydroxypyridinone compound transforming the hydroxyl group on the main ring into an N,N-dimethylcarbamate group; in the course of that study we developed a computational model to screen compounds for enzymatic activity. Herein we report development of second generation libraries. Candidates that adhere to drug-like criteria from a virtual library of compounds were tested using computational docking studies. Synthesis and characterization of chosen test compounds and their acetylcholinesterase inhibitory activity are presented.

Phenylethylene glycol-derived LpxC inhibitors with diverse Zn2+-binding groups

Galster, Magdalena,L?ppenberg, Marius,Galla, Fabian,B?rgel, Frederik,Agoglitta, Oriana,Kirchmair, Johannes,Holl, Ralph

, p. 486 - 509 (2019)

The Zn2+-dependent bacterial deacetylase LpxC is a promising target for the development of novel antibiotics. Most of the known LpxC inhibitors carry a hydroxamate moiety as Zn2+-binding group. However, hydroxamic acids generally exh

Preparation method of intermediate of antiviral drug

-

Paragraph 0061-0064, (2021/06/22)

The invention relates to a preparation method of an intermediate of an antiviral drug, belonging to the field of medicinal chemistry. According to the method provided by the invention, raw materials react with an alkene forming reagent under the condition that Lewis acid and acid anhydride are added to prepare an intermediate compound; and then the intermediate compound reacts under the action of sodium periodate, and then post-treatment is conducted under the conditions of alkali and an oxidizing agent to obtain the intermediate. According to the method disclosed by the invention, reagents with relatively high toxicity or relatively high price and conditions such as extremely low temperature which is difficult to reach or control are not needed, used reagents are cheap and easy to obtain, reaction conditions are easy to control and implement, and the method has relatively high industrial application value.

Polycyclic pyridine oxime-based compound as well as pharmaceutical composition and application thereof

-

Paragraph 0150-0153, (2021/11/26)

The invention discloses a polycyclic pyridine oxime-based compound and a pharmaceutical composition and application thereof, wherein the polycyclic pyridine oxime-based compound is shown as a formula (I). The compound shows strong inhibition of influenza

Design, synthesis and biological evaluation of potential anti-AD hybrids with monoamine oxidase B inhibitory and iron-chelating effects

Guo, Jianan,Mi, Zhisheng,Jiang, Xiaoying,Zhang, Changjun,Guo, Zili,Li, Linzi,Gu, Jinping,Zhou, Tao,Bai, Renren,Xie, Yuanyuan

, (2020/12/29)

A series of active hybrids combining 3-hydroxypyridin-4(1H)-one and coumarin pharmacophores were designed and synthesized as potential agents for the treatment of Alzheimer's disease (AD). All the compounds exhibited excellent iron-chelating activities (p

Design, synthesis and biological evaluation of a series of iron and copper chelating deferiprone derivatives as new agents active against Candida albicans

Bortolami, Martina,Pandolfi, Fabiana,Messore, Antonella,Rocco, Daniele,Feroci, Marta,Di Santo, Roberto,De Vita, Daniela,Costi, Roberta,Cascarino, Paola,Simonetti, Giovanna,Scipione, Luigi

, (2021/05/13)

Candida albicans, in specific conditions, is responsible of severe invasive systemic candidiasis that are related to its ability to produce biofilm on biological and artificial surfaces. Many studies reported the role of iron in fungal growth and virulence and the ability of metal chelating agents to interfere with C. albicans metabolism, virulence and biofilm formation. Here we report the activity of 3-hydroxy-1,2-dimethyl-4(1H)-pyridinone (deferiprone) derivatives against C. albicans planktonic cells and biofilm. Some of the studied compounds (2b and 3b) were able to chelate Fe(III) and Cu(II), and showed an interesting activity on planktonic cells (MIC50 of 32 μg/mL and 16 μg/mL respectively) and on biofilm formation (BMIC50 of 32 μg/mL and 16 μg/mL respectively) in cultured ATCC 10,231C. albicans; this activity was reduced, in a concentration dependent way, by the addition of Fe(III) and Cu(II) to the culture media. Furthermore, the most active compound 3b showed a low toxicity on Galleria mellonella larvae.

Design and synthesis of N-hydroxyalkyl substituted deferiprone: a kind of iron chelating agents for Parkinson's disease chelation therapy strategy

Zhang, Qingchun,Feng, Shufan,Zhao, Yulian,Jin, Bo,Peng, Rufang

, p. 467 - 478 (2021/05/13)

The blood–brain barrier (BBB) permeability of molecules needs to meet stringent requirements of Lipinski’s rule, which pose a difficulty for the rational design of efficient chelating agents for Parkinson's disease chelation therapy. Therefore, the iron c

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 61049-69-2